RxSight price target raised to $34 from $27 at Needham

Needham raised the firm’s price target on RxSight to $34 from $27 and keeps a Buy rating on the shares. The firm states that its checks were throughout the quarter were positive for the company, and it sees upside to utilization and margins when RxSight reports Q2 results. Based on investor conversations, RxSight also remains a somewhat under the radar stock, the analyst tells investors in a research note.